Monday, November 21, 1994
Oppenheimer & Co. analyst Matthew Geller raised Amgen Inc. to a "buy" from "market performer," prior to Friday's announcement of the deal with Synergen Inc. He said that if Ciba-Geigy takes a substantial equity stake in Chiron Corp.
, it would leave AMGN, and perhaps Biogen Inc.
, as the best potential buy-in or takeover candidate in biotechnology.